ArticleScientific reports2026
Effects of cellular receptors on the vaccine efficacies of adenovirus vector-based vaccines following intramuscular and intranasal administration.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Adenovirus (Ad) vectors are a promising next-generation vaccine modality currently under development. An Ad particle is composed of three major capsid proteins—fiber, penton base, and hexon—that play critical roles in cellular entry. However, the extents to which the receptor-mediated cellular entry pathways influence the efficacy of Ad vector-based vaccines are not well understood. In this study, we examined the effects of the cellular uptake pathway on the vaccine efficacy of Ad vectors by using the β-galactosidase (β-gal)-expressing, capsid-modified Ad vectors that utilize the different cellular entry routes. Following intramuscular vaccination, all capsid-modified Ad vectors induced serum anti-β-gal antibody levels comparable to those induced by the conventional Ad vector. In contrast, after intranasal vaccination, the Ad vectors with mutations in the penton base or hexon elicited anti-β-gal antibody titers in the serum, bronchoalveolar lavage fluid (BALF), and nasal wash at levels comparable with the conventional Ad vector. On the other hand, the coxsackievirus-adenovirus receptor (CAR)-binding-ablated Ad vector exhibited a significant reduction in the anti-β-gal IgG titers in the serum and BALF, and anti-β-gal IgA titers in the BALF and nasal wash. These findings highlight that CAR-mediated transduction is crucial for efficient vaccination with an Ad vector after intranasal administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.